keyword
https://read.qxmd.com/read/37942464/epidemiology-and-risk-factors-for-invasive-fungal-infections-in-pancreas-transplant-in-the-absence-of-postoperative-antifungal-prophylaxis
#21
JOURNAL ARTICLE
Jessica Zachary, Jeanne M Chen, Asif Sharfuddin, Muhammad Yaqub, Andrew Lutz, John Powelson, Jonathan A Fridell, Nicolas Barros
BACKGROUND: Invasive fungal infections (IFIs) remain a rare yet dreaded complication following pancreas transplantation. Current guidelines recommend antifungal prophylaxis in patients with 1 or more risk factors. At our center, single-dose antifungal prophylaxis is administered in the operating room but none subsequently, regardless of risk factors. Here we evaluate the 1-year incidence, outcome, and risk factors associated with IFI following pancreas transplantation. METHODS: A retrospective, single-center cohort study was conducted in patients who underwent pancreas transplantation between 1 January 2009 and 31 December 2019...
November 2023: Open Forum Infectious Diseases
https://read.qxmd.com/read/37827978/real-world-investigation-of-eosinophilic-associated-disease-overlap-reveal-analysis-of-a-us-claims-database
#22
JOURNAL ARTICLE
Anamaria Brailean, Justin Kwiatek, Danuta Kielar, Rohit Katial, Xia Wang, Xiao Xu, Yong Jin Kim, Michael Stokes, Heide A Stirnadel-Farrant
PURPOSE: The epidemiology of eosinophil-associated diseases (EADs) is not yet fully understood. While some studies have been conducted on stand-alone eosinophilic diseases, there is scarce evidence on the degree of overlap among rarer conditions. METHODS: The retrospective Real-world inVestigation of Eosinophilic-Associated disease overLap (REVEAL) study used data from the Optum® Clinformatics® insurance claims database to describe and characterize disease overlap among 11 EADs: allergic bronchopulmonary aspergillosis, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic gastritis/gastroenteritis, eosinophilic granulomatosis with polyangiitis, eosinophilic esophagitis, bullous pemphigoid, chronic obstructive pulmonary disorder, chronic spontaneous urticaria, and non-cystic fibrosis bronchiectasis...
September 2023: Allergy, Asthma & Immunology Research
https://read.qxmd.com/read/37806994/diagnostic-utility-of-galactomannan-enzyme-immunoassay-in-invasive-aspergillosis-in-pediatric-patients-with-hematological-malignancy
#23
JOURNAL ARTICLE
Sutapa Das, Malini R Capoor, Amitabh Singh, Yatish Agarwal
OBJECTIVE: This study aims to determine the diagnostic utility of galactomannan enzyme immunoassay (GM EIA) in invasive aspergillosis (IA) in children with hematological malignancy (high risk population) in terms of sensitivity, specificity, negative predictive value (NPV) and positive predictive values (PPV) at various cut offs while validating the revised EORTC/MSG 2019 criteria in order to obtain the best cut-off. MATERIAL AND METHODS: For 100 pediatric patients, serum and respiratory samples were collected...
October 9, 2023: Mycopathologia
https://read.qxmd.com/read/37799220/clinical-microbiological-serological-and-radiological-profile-of-patients-with-mild-moderate-and-severe-allergic-bronchopulmonary-aspergillosis-abpa
#24
JOURNAL ARTICLE
Amardeep Singh, Umma Sadia Tomo, Manoj Kumar Dodiya, Pankaj K Singh, Abdul Manan, Inimerla Bhavya, Varsha S Kumar, Irfan A Mir
Objective Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus antigen mostly Aspergillus fumigatus that occurs almost exclusively in patients with asthma and cystic fibrosis. ABPA is an underdiagnosed and undertreated disease because of its presentation with various grades of severity in asthma patients. Data available regarding the clinical, serological, and radiological profile of ABPA patients is limited due to lack of consensus on diagnostic criteria and treatment guidelines...
September 2023: Curēus
https://read.qxmd.com/read/37799179/opportunistic-fungal-invasion-in-covid-19-pandemic-a-critical-review-in-diagnosis-and-management
#25
REVIEW
Abhishek Sharma, Gulnaz Bano, Abdul Malik, Yuman Rasool, Samrina Manzar, Tarun Singh, Manish Maity
Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is the culprit behind the pandemic across the globe in recent decades. Variants of SARS-CoV especially coronavirus disease 2019 (COVID-19)-related fungus might not be identified or might be misdiagnosed on a worldwide scale. Patients of COVID-19 acquired invasive mycoses, especially if they are very ill or immunosuppressed. Clinical intervention based on various standard guidelines would be necessary to guarantee that Aspergillus and Candida -infected COVID-19 patients are adequately treated...
July 2023: Avicenna Journal of Medicine
https://read.qxmd.com/read/37764073/real-world-multicenter-case-series-of-patients-treated-with-isavuconazole-for-invasive-fungal-disease-in-china
#26
JOURNAL ARTICLE
Lisha Wu, Shougang Li, Weixi Gao, Xiaojian Zhu, Pan Luo, Dong Xu, Dong Liu, Yan He
BACKGROUND: The incidence of invasive fungal disease (IFD) has increased significantly, and IFD is a major cause of mortality among those with hematological malignancies. As a novel second-generation triazole antifungal drug offering both efficacy and safety, isavuconazole (ISA) is recommended by various guidelines internationally for the first-line treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) infecting adults. Given that it was only approved in China at the end of 2021, there is currently a lack of statistical data regarding its usage in the Chinese population...
September 4, 2023: Microorganisms
https://read.qxmd.com/read/37729658/duration-of-antifungal-treatment-in-mold-infection-when-is-enough
#27
REVIEW
Vera Portillo, Dionysios Neofytos
PURPOSE OF REVIEW: Although invasive mold infections (IMI) are a major complication in high-risk populations, treatment duration has not yet been well defined. RECENT FINDINGS: Guidelines suggest documenting clinical/radiological resolution and immunological recovery before stopping antifungal treatment, after a minimum duration of treatment of 3 months for invasive pulmonary aspergillosis, while longer (up to 6 months) duration is proposed for the treatment of invasive mucormycosis...
December 1, 2023: Current Opinion in Infectious Diseases
https://read.qxmd.com/read/37624041/utility-of-in-house-and-commercial-pcr-assay-in-diagnosis-of-covid-19-associated-mucormycoss-in-an-emergency-setting-in-a-tertiary-care-center
#28
JOURNAL ARTICLE
Mragnayani Pandey, Janya Sachdev, Renu Kumari Yadav, Neha Sharad, Anupam Kanodia, Jaya Biswas, R Sruti Janani, Sonakshi Gupta, Gagandeep Singh, Meera Ekka, Bhaskar Rana, Sudesh Gourav, Alok Thakar, Ashutosh Biswas, Kapil Sikka, Purva Mathur, Neelam Pushker, Viveka P Jyotsna, Rakesh Kumar, Manish Soneja, Naveet Wig, M V Padma Srivastava, Immaculata Xess
Introduction. Invasive mucormycosis (IM) is a potentially fatal infection caused by fungi of the order Mucorales . Histopathology, culture, and radiology are the mainstays of diagnosis, but they are not sufficiently sensitive, resulting in delayed diagnosis and intervention. Recent studies have shown that PCR-based techniques can be a promising way to diagnose IM. Hypothesis/Gap Statement. Early diagnosis of fungal infections using molecular diagnostic techniques can improve patient outcomes, especially in invasive mucormycosis...
August 2023: Journal of Medical Microbiology
https://read.qxmd.com/read/37604274/lung-and-sinus-fungal-infection-imaging-in-immunocompromised-patients
#29
REVIEW
Frederic Lamoth, Katya Prakash, Catherine Beigelman-Aubry, John W Baddley
BACKGROUND: Imaging is a key diagnostic modality for suspected invasive pulmonary or sinus fungal disease and may help to direct testing and treatment. Fungal diagnostic guidelines have been developed and emphasize the role of imaging in this setting. We review and summarize evidence regarding imaging for fungal pulmonary and sinus disease (in particular invasive aspergillosis, mucormycosis and pneumocystosis) in immunocompromised patients. OBJECTIVES: We reviewed data on imaging modalities and findings used for diagnosis of invasive fungal pulmonary and sinus disease...
August 20, 2023: Clinical Microbiology and Infection
https://read.qxmd.com/read/37562901/chronic-pulmonary-aspergillosis-in-a-tertiary-tuberculosis-institute-a-common-entity-missed-commonly
#30
REVIEW
Ritu Singhal, Amitesh Gupta, Neeta Singla, Rupak Singla, Ritika Jha, Shweta Raina, Madhumita Paul Choudhary, Nilotpal Bhattacherjee
The disease chronic pulmonary aspergillosis (CPA), which has 3 million cases globally, has a substantial impact on global health. The morbidity and mortality it cause are also rather severe. Patients with modest immune suppression or those with underlying structural and chronic lung illnesses are more likely to develop this condition. CPA pose a diagnostic and management challenge to clinicians. The condition causes patients to have persistent respiratory difficulties, which lowers their quality of life, and the therapy is lengthy and offers few choices...
July 2023: Indian Journal of Tuberculosis
https://read.qxmd.com/read/37526790/itraconazole-serum-trough-concentrations-using-oral-capsules-for-the-treatment-of-chronic-pulmonary-aspergillosis-what-is-the-target
#31
JOURNAL ARTICLE
Vítor Falcão de Oliveira, Mariane Taborda, Vitor Ciampone Arcieri, Wdson Luis Lima Kruschewsky, Andre Nathan Costa, Nilo José Coêlho Duarte, Paschoalina Romano, Persio de Almeida Rezende Ebner, Adriana Satie Gonçalves Kono Magri, Edson Abdala, Anna S Levin, Marcello Mihailenko Chaves Magri
BACKGROUND: In regions where there is only itraconazole capsule as a therapeutic option for treatment of chronic pulmonary aspergillosis (CPA), measuring the serum concentrations becomes even more important for therapeutic success. OBJECTIVE: Evaluate the initial itraconazole serum trough concentrations after the administration of oral capsule of itraconazole for the treatment of CPA. METHODS: The measurement was performed at least 7-days after initiation of therapy...
August 1, 2023: Mycopathologia
https://read.qxmd.com/read/37508292/clinical-and-microbiological-outcomes-and-follow-up-of-secondary-bacterial-and-fungal-infections-among-critically-ill-covid-19-adult-patients-treated-with-and-without-immunomodulation-a-prospective-cohort-study
#32
JOURNAL ARTICLE
Bálint Gergely Szabó, Eszter Czél, Imola Nagy, Dorina Korózs, Borisz Petrik, Bence Marosi, Zsófia Gáspár, Martin Rajmon, Márk Di Giovanni, István Vályi-Nagy, János Sinkó, Botond Lakatos, Ilona Bobek
BACKGROUND: Nearly 10% of COVID-19 cases will require admission to the intensive care unit (ICU). Our aim was to assess the clinical and microbiological outcomes of secondary infections among critically ill COVID-19 adult patients treated with/without immunomodulation. METHODS: A prospective observational cohort study was performed between 2020 and 2022 at a single ICU. The diagnosis and severity classification were established by the ECDC and WHO criteria, respectively...
July 17, 2023: Antibiotics
https://read.qxmd.com/read/37362371/decoding-the-guidelines-of-invasive-pulmonary-aspergillosis-in-critical-care-setting-imaging-perspective
#33
REVIEW
Anisha Garg, Ashu Seith Bhalla, Priyanka Naranje, Surabhi Vyas, Mandeep Garg
Invasive pulmonary aspergillosis (IPA) is a common, life-threatening opportunistic fungal infection seen in susceptible individuals especially those admitted in critical care units. Multiple guidelines have been promulgated for the diagnosis of IPA, some of which are all inclusive, while others cater to specific patient groups. Microbiology forms the crux of the majority of the diagnostic tests/criteria; however, results take a considerable amount of time. Radiology can play an important role by bridging the gap to reach at an early diagnosis...
July 2023: Indian Journal of Radiology & Imaging
https://read.qxmd.com/read/37264275/evidence-based-guidelines-for-the-management-of-allergic-bronchopulmonary-aspergillosis-abpa-in-children-and-adolescents-with-asthma
#34
REVIEW
Joseph L Mathew, Ketan Kumar, Sheetal Agrawal, Sanjay Bafna, Sonia Bhatt, Pallab Chatterjee, N S Chithambaram, Rashmi Ranjan Das, Hema Gupta, Sarika Gupta, Kana Ram Jat, Pawan Kalyan, Rashmi Kapoor, Hardeep Kaur, Jasmeet Kaur, Satnam Kaur, Suhas P Kulkarni, Amber Kumar, Sanjiv Singh Rawat, Vivek Saxena, Anita Singh, Somu Sivabalan, Shetanshu Srivastava, Anshula Tayal
BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) frequently complicates asthma. There is urgent need to develop evidence-based guidelines for the management of ABPA in children. The Evidence Based Guideline Development Group (EBGDG) of the Indian Academy of Pediatrics (IAP) National Respiratory Chapter (NRC) addressed this need. METHODS: The EBGDG shortlisted clinical questions relevant to the management of ABPA in asthma. For each question, the EBGDG undertook a systematic, step-wise evidence search for existing guidelines, followed by systematic reviews, followed by primary research studies...
June 2, 2023: Indian Journal of Pediatrics
https://read.qxmd.com/read/37256502/a-tale-of-two-hospitals-comparing-capa-infections-in-two-icus-during-the-spanish-fourth-pandemic-wave
#35
JOURNAL ARTICLE
Miguel Ángel Sánchez-Castellano, Cristina Marcelo, Javier Marco, Juan Carlos Figueira-Iglesias, Julio García-Rodríguez
PURPOSE: COVID-19 associated pulmonary aspergillosis (CAPA) is a new clinical entity linked to SARS-CoV-2 infection that is causing a rise on the risk of complications and mortality, particularly in critical patients. METHODS: We compared diagnostic and clinical features in two cohorts of patients with severe COVID-19 admitted in the intensive care units (ICU) of two different hospitals in Madrid, Spain, between February and June 2021. Clinical and microbiological relevant aspects for CAPA diagnosis were collected for further classification...
May 31, 2023: Mycopathologia
https://read.qxmd.com/read/37104686/evolution-of-antifungals-for-invasive-mold-infections-in-immunocompromised-hosts-then-and-now
#36
REVIEW
Zoe Freeman Weiss, Jessica Little, Sarah Hammond
INTRODUCTION: The current armamentarium of antifungal agents for invasive mold infections (IMI) has dramatically improved over the last 50 years. Existing therapies are, however, associated with toxicities, drug interactions, and, in some cases, therapeutic failures. Novel antifungals are needed to address the increasing prevalence of IMI and the growing threat of antifungal resistance. AREAS COVERED: We review the history and development of the most commonly used antifungals...
May 2023: Expert Review of Anti-infective Therapy
https://read.qxmd.com/read/37097150/retrospective-multicenter-evaluation-of-the-virclia-galactomannan-antigen-assay-for-the-diagnosis-of-pulmonary-aspergillosis-with-bronchoalveolar-lavage-fluid-samples-from-patients-with-hematological-disease
#37
JOURNAL ARTICLE
Jochem B Buil, Sammy Huygens, Albert Dunbar, Alexander Schauwvlieghe, Marijke Reynders, Diana Langerak, Karin van Dijk, Anke Bruns, Pieter-Jan Haas, Douwe F Postma, Bart Biemond, Fatima Zohra Delma, Elizabeth de Kort, Willem J G Melchers, Paul E Verweij, Bart Rijnders
Galactomannan (GM) testing of bronchoalveolar lavage (BAL) fluid samples has become an essential tool to diagnose invasive pulmonary aspergillosis (IPA) and is part of diagnostic guidelines. Enzyme-linked immunosorbent assays (ELISAs) (enzyme immunoassays [EIAs]) are commonly used, but they have a long turnaround time. In this study, we evaluated the performance of an automated chemiluminescence immunoassay (CLIA) with BAL fluid samples. This was a multicenter retrospective study in the Netherlands and Belgium...
April 25, 2023: Journal of Clinical Microbiology
https://read.qxmd.com/read/37077251/salvage-treatment-for-invasive-aspergillosis-and-mucormycosis-challenges-recommendations-and-future-considerations
#38
REVIEW
Matthias Egger, Romuald Bellmann, Robert Krause, Johannes Boyer, Daniela Jakšić, Martin Hoenigl
Invasive mold diseases are devastating systemic infections which demand meticulous care in selection, dosing, and therapy monitoring of antifungal drugs. Various circumstances regarding PK/PD properties of the applied drug, resistance/tolerance of the causative pathogen or host intolerability can lead to failure of the initial antifungal therapy. This necessitates treatment adaption in the sense of switching antifungal drug class or potentially adding another drug for a combination therapy approach. In the current state of drastically limited options of antifungal drug classes adaption of therapy remains challenging...
2023: Infection and Drug Resistance
https://read.qxmd.com/read/37059587/physicians-knowledge-of-invasive-fungal-disease-in-china
#39
JOURNAL ARTICLE
Yijian Chen, Xiaojun Huang, Haibo Qiu, Linling Cheng, Yunsong Yu, Xiaochun Ma, Sizhou Feng, Qi Li, Depei Wu, Wenxiang Huang, Dechang Chen, Xiaoju Lv, Jianda Hu, Jingbo Wang, Jiabin Li, Wenjie Yang, Qingyuan Zhan, Bing Sun, Minggui Wang
BACKGROUND: Invasive fungal disease (IFD) is associated with high morbidity and mortality. Data are lacking regarding physicians' perspectives on the diagnosis and management of IFD in China. OBJECTIVES: To evaluate physicians' perspectives on the diagnosis and management of IFD. METHODS: Based on current guidelines, a questionnaire was designed and administered to 294 physicians working in haematology departments, intensive care units, respiratory departments and infectious diseases departments in 18 hospitals in China...
April 14, 2023: Mycoses
https://read.qxmd.com/read/37022291/invasive-pulmonary-aspergillosis-in-the-intensive-care-unit-current-challenges-and-best-practices
#40
REVIEW
Sarah Gaffney, Dearbhla M Kelly, Puteri Maisarah Rameli, Eoin Kelleher, Ignacio Martin-Loeches
The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID-19) infection. It continues to represent both a diagnostic and therapeutic challenge and can be associated with significant morbidity and mortality. In this narrative review, we describe the epidemiology, risk factors and disease manifestations of IPA...
November 2023: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
keyword
keyword
52809
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.